124724-88-5

Basic information

• Product Name: 1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)-
• Synonyms: 1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)-;(S)-5-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-one
• CAS NO: 124724-88-5
• Molecular Formula: C₇H₁₂O₄
• Molecular Weight: 160.16778
• Mol File: 124724-88-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)-(124724-88-5)
• EPA Substance Registry System: 1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)-(124724-88-5)

Safety Data

• Hazardous Substances Data: 124724-88-5(Hazardous Substances Data)

Usage

General Description

1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)- is a chemical compound that is also known as 5-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-one. It is an organic compound with the molecular formula C7H12O3 and has a molecular weight of 144.17 g/mol. 1,3-Dioxolan-4-one, 5-(2-hydroxyethyl)-2,2-dimethyl-, (5S)- is a cyclic carbonate and is commonly used as a solvent or as a precursor in the synthesis of other organic compounds. It is a colorless liquid with a fruity odor and is soluble in water, making it a versatile and useful chemical in various industries including pharmaceuticals, polymers, and cosmetics.

Upstream product

• 97-67-6 (S)-Malic acid 
• 77-76-9 2,2-dimethoxy-propane 
• 113278-68-5 2-[(4S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid 

Downstream Products

• 870460-32-5 2,6-di-tert-butyl-4-(1-{3,5-di-tert-butyl-4-[2-(2,2-dimethyl-[1,3]dioxolan-4(S)-yl)-ethoxy]-phenylsulfanyl}-1-methyl-ethylsulfanyl)-phenol 
• 174563-84-9 (S)-5-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-one p-toluenesulfonate 
• 52079-23-9 (3S)-3-hydroxydihydrofuran-2(3H)-one 
• 124724-89-6 Benzoic acid 2-((S)-2,2-dimethyl-5-oxo-[1,3]dioxolan-4-yl)-ethyl ester 

Relevant articles and documents

Preparation method of alpha-hydroxyl-gamma-butyrolactone

The invention belongs to the field of preparation of organic compounds, and provides a preparation method of alpha-hydroxyl-gamma-butyrolactone. The method is characterized in that malic acid is used as a raw material, and alpha-hydroxyl-gamma-butyrolactone is synthesized with high yield through four steps of reactions, namely, carboxyl and alpha-hydroxyl protection, beta-carboxyl reduction, protecting group removal and internal esterification. The method has the advantages of easily available raw materials, mild reaction conditions and low cost, and is suitable for large-scale preparation of alpha-hydroxy-gamma-butyrolactone.

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

STIMULUS-RESPONSIVE POLY(LACTIC-CO-GLYCOLIC)-BASED POLYMERS AND NANOPARTICLES FORMED THEREFROM

PLGA-based polymers include pendant nucleophiles protected with photocleavable protecting groups. Upon deprotection, the polymers degrade rapidly via intramolecular cyclization into small molecules. The polymer may be formulated as a nanoparticle, with an encapsulated payload, which may be an imaging agent, a bioactive agent or a pharmaceutical agent.

Light-triggered intramolecular cyclization in poly(lactic- co -glycolic acid)-based polymers for controlled degradation

Polylactide (PLA) and poly(dl-lactide-co-glycolide) (PLGA) are two prominent FDA-approved polymers because of their useful biodegradation into largely innocuous substances. Their hydrolytic degradation is slow and offers minimal control over degradation kinetics, especially in the minutes time scale. However, molecular engineering of their structures could allow triggered degradation. We have synthesized, by ring-opening polymerization (ROP), a series of PLGA-based polymers containing pendant nucleophiles protected with photocleavable groups. Upon deprotection, two of the polymers degrade rapidly via intramolecular cyclization into small molecules. Nanoparticles formulated from these polymers undergo rapid structural changes in response to UV light. This work introduces a novel polymeric structure to enable rapid on-demand degradation and expands the library of polymers that degrade by cyclization.

SYNTHETIC PRECURSOR OF EPOTHILONE FOR IMPROVING PRODUCTION OF EPOTHILONE AND METHOD FOR PREPARING EPOTHILONE USING THE SAME

The present invention relates to a compound for increasing production of epothilone in actinomyces, and to a method for producing epothilone with increased yield. The method for producing epothilone of the present invention includes a step of culturing actinomyces in which epothilone-biosynthesizing genes in Sorangium cellulosum including epoD, epoE, epoF, orf6, orf3, and orf14 are introduced in a culture medium. According to the present invention, it is possible to increase the production yield of epothilone in actinomyces, even in actinomyces in which epoA, epoP, epoB, and epoC are not introduced therein.COPYRIGHT KIPO 2016

NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS

The invention provides compounds, pharmaceutical compositions and methods of treatment of inflammatory disorders including a compound of Formula I, or its pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative or prodrug wherein R

A METHOD FOR PREPARING 4-Y9-(6-AMINOPURINE)¨-2-(S)-HYDROXYL-BUTYRIC ACID METHYL ESTER

The present invention discloses a novel method for preparing and purifying 4-(6-Amino-purin-9-yl)-2(S)-hydroxy-butyric acid methyl ester. The preparation started from cheap and easily available L-malic acid, which was transformed to intermediate I after s

Synthesis and biological evaluation of immunosuppressive agent DZ2002 and its stereoisomers

DZ2002 and its related stereoisomers were efficiently synthesized. The optical data of (R)- and (S)-DZ2002 were disclosed here for the first time. Their inhibitory potency was evaluated on SAHase and MLR assay in the mean time. In accordance with respecti

A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor

The synthesis of the major metabolite of a potent 3-aminopyrazole CDK2/cyclin A inhibitor is presented. A stereoconservative approach starting from malic acid was employed to construct the hydroxy-substituted pyrrolidinone moiety. In the key step of the s

Design and synthesis of novel metalloproteinase inhibitors

A series of N-benzoyl 4-aminobutyric acid hydroxamate analogs were synthesized and evaluated as matrix metalloproteinase inhibitors. Synthetic work was focused on the chemical modification of the 4-aminobutyric acid part using easily available starting materials. As such, chemical modification was carried out using commercially available starting materials such as 4-aminobutyric acid, (+)- and (-)-malic acid, and d- and l-glutamic acid derivatives. Among the compounds tested, N-[4-(benzofuran-2-yl)benzoyl] 4-amino-4S-hydroxymethylbutyric acid hydroxamates derived from l-glutamic acid demonstrated more potent inhibitory activity against MMP-2 and MMP-9 compared with the corresponding 2S-hydroxy analogs or 3S-hydroxy analogs, respectively, which were derived from (-)-malic acid. Structure-activity relationship study is presented.